Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Name | Title | Since | Age |
|---|---|---|---|
| Nir Nimrodi | Independent Chairman | 2025 | 57 |
| Ofer Haviv | CEO, President & Director | 2025 | 60 |
| Dan Falk | Independent Director | 2021 | 81 |
| Leon Y. Recanati | Independent Director | 2005 | 78 |
| Sarit Weiss-Firon | Independent Director | 2021 | 59 |
| Adrian Percy | Independent Director | 2019 | 61 |
| John J. Irwin | Member of Scientific Advisory Board | 2026 | - |
| Dan T. Major | Member of Scientific Advisory Board | 2026 | - |